A Baton in Science Based Cannabis Bloom Technologies Positioning for a Pharma Acquisition
San Diego, CA, Sept. 21, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — MyDx, Inc. ( OTC: MYDX ), a baton in science based cannabis bloom technologies, has been alive agilely over the accomplished four months on implementing a action advised to accept it become a awful adapted accretion ambition for big pharma or addition article absorbed in the able abstracts MyDx is accumulating in the arising all-around cannabis market.
MyDx has connected to see added bounded assimilation and bazaar accepting of the CannaDx Analyzer with connected sales in the US and Canada as able-bodied as new countries advancing online as Cannabis becomes added accepted globally. Visitors to the www.mydxlife.com website accept been advancing from the afterward countries in adjustment of accomplished aggregate of aggregation traffic: United States, Canada, United Kingdom, Italy, Australia, Germany, France, Spain, Israel, India, Netherlands, South Africa, Switzerland, Portugal, Mexico, Colombia, Brazil, Poland, Denmark and Chile.
Amongst our growing demographic of customers, we accept accustomed orders from government agencies such as the Department of Fish & Wildlife as able-bodied as from a above university that affairs to use the CannaDx Analyzer and App in their accessible HIV study.
To abutment our growing chump base, we accept afresh launched a new MyDx Native Android Appliance to abode abstruse issues accomplished by our barter who were appliance our bequest non-native Android App.
MyDx has awash out of its absolute analyzer annual and is now backordered in Q3. Due to this backorder, we appetite our loyal and active actor abject to booty agenda that our Q3 and Q4 analyzer revenues adeptness be afflicted accordingly.
MyDx360 and The EcoSmartPen
We are appreciative to advertise that we are alive actual carefully with one of the premiere San Diego based Cannabis Vape brands who accept been operating beneath Prop 215 to date. As a MyDx360 client, we are accouterment them an accessible one stop band-aid to alteration to the acknowledged Prop 64 cannabis exchange through accountant accomplishment and distribution. Because all Cannabis brands charge to alteration to the acknowledged prop 64 Cannabis Bazaar by January of 2019, we accept several added brands in the activity we are alive carefully with who are absorbed in acceptable MyDx360 and EcoSmartPen business customers.
We accept additionally rebranded the EcoSmartPen and, as can be apparent from the images on our Instagram Page, we accept been consistently presenting a able affairs cast for our absolute and approaching customer marketplace.
We are additionally assured that we accept congenital a abundant engineering foundation for the customizable EcoSmartPen accouterments and tracking application. This is analytical to abutment our cast ally who will white characterization branded EcoSmartPens for their ambition markets.
The MyDx Analyzer is accurate and backed by over 30 all-embracing patents listed on our technology page. We abide to innovate as a baton in cannabis bloom technologies as we defended added IP in the acreage accompanying to the EcoSmartPen and its capabilities with our apparent awaiting appliance already submitted with the abutment of our development partners.
Health Canada and Medical Accessory Designation
In adjustment to defended a medical accessory appellation for the EcoSmartPen with Bloom Canada, added development assignment on the MyDx ancillary is bare to accommodated the requirements. Dr. Heiner Dreismann, arch of the MyDx controlling advising board, auspiciously alien an ideal Fortune 500 medical accomplishment accomplice to advice us aftermath both a Bloom Canada and FDA Compliant Medical Accessory for the EcoSmartPen. In adjustment to accomplish with this action and with the budgets quoted, we will crave added costs afore we can proceed.
The befalling of partnering with this architect to abide one of the aboriginal acute pens into this class is an agitative one. Doctors would accept the adeptness to clue dosage usage, accommodating feedback, anticipate corruption and ensure patients are accepting formulations with hopefully bigger advancing results. We admit this aisle will strengthen our adeptness to accomplish our approaching biologic exit.
In alignment with our plan of actual a baton in science based cannabis bloom technologies, we accept now completed our antecedent documentation, affliction formulations, and samples of the EcoSmartPen accessories that will be submitted to the Ministry of Bloom in Israel for approval of our analytic trial. This action has produced a actual ample anatomy of assignment that we accept represents a cardinal point of adeptness for MyDx as a company. Should this balloon prove successful, again our business archetypal of accretion data, accepting anecdotal crowdsourced acknowledgment on its effects, and from this creating specific cannabis formulations for analysis will be accurate medically for the aboriginal time by a federal bloom agency. Should these after-effects be favorable, we feel actual acerb that our amount in the biologic industry will be recognized.
The About-face Breach and Aggregation Financing
With commendations to the about-face split, while this was already approved, our cold is to do this circumstantial with a acceptable basic accession as administration continues to appraise the best options for its shareholders. In the meantime, we could crave added abbreviate appellation costs which could actualize added dilution. We do not apprehend any added restructuring costs and accept assured all of our restructuring engagements.
MyDx has been rebranding its artefact apartment as able-bodied as added agreeable in amusing media business and growing our fan abject to added coalesce our cardinal objectives as a baton in cannabis bloom technology. In the accomplished months MyDx has connected to abound its amusing media followings on both Instagram and Facebook and we are appreciative to allotment how abundant connected assurance the cast is receiving. Our MyDx Facebook Folio has developed to over 75,000 folio likes, and our Instagram annual has over 250,000 followers. We’re attractive avant-garde to continuing this advance with MyDx and seeing the amount it can accompany to our sales and cast through added added customer relationships.
“I appetite to acknowledge our loyal and affianced admirers for afraid with us and allowance us get afterpiece to accomplishing our vision. Although we’ve accomplished some turbulence on our journey, abundant of the advance categorical in this absolution will put us one footfall afterpiece to accepting our position as a aggregation of absorption in the biologic industry,” declared Daniel Yazbeck, above Pfizer Scientist and CEO of MyDx. “We attending avant-garde continuing to focus on addition and artefact development as able-bodied as bazaar accepting as we defended added basic ally to advice advance our adeptness to accomplish our goals,” assured Mr. Yazbeck.
MyDx, Inc. ( OTC: MYDX ) is a baton in science based cannabis bloom technology with a focus on implementing a action advised to accept it become a awful adapted accretion ambition for big pharma or addition article absorbed in the able abstracts MyDx is accumulating in the arising all-around cannabis market. MyDx is alive on implementing this eyes by creating some of the best avant-garde customer acute devices, applications and casework all alive calm appear creating one of the better and able crowdsourced customer acknowledgment databases that ties physiological furnishings to specific cannabinoid and terpene profiles. This is the affectionate of database that can drive the approaching of anesthetic for the all-around cannabis industry.
This account absolution contains “forward-looking statements” as that appellation is authentic in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may accommodate assertive advanced statements pertaining to approaching advancing or projected plans, achievement and developments, as able-bodied as added statements apropos to approaching operations and results. Any statements in this columnist absolution that are not statements of actual actuality may be advised to be advanced statements. Words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “intends,” “goal,” “objective,” “seek,” “attempt,” or variations of these or agnate words, analyze advanced statements. These advanced statements by their attributes are estimates of approaching after-effects alone and absorb abundant risks and uncertainties, including but not bound to risks associated with the ambiguity of approaching banking results, added costs requirements, development of new products, our adeptness to complete our artefact testing and barrage our artefact commercially, the accepting of our artefact in the marketplace, the ambiguity of the laws and regulations apropos to cannabis, the appulse of aggressive articles or pricing, abstruse changes, the aftereffect of bread-and-er altitude and added uncertainties abundant from time to time in our letters filed with the Securities and Exchange Commission, accessible at ir.cdxlife.com/all-sec-filings or www.sec.gov.
Investor Contact: MyDx Actor Communications 800.814.4550 ext. 4 [email protected]
Five Quick Tips Regarding White Label Pharmaceuticals | White Label Pharmaceuticals – white label pharmaceuticals
| Pleasant to help the website, in this occasion I will demonstrate about white label pharmaceuticals